News Search Results
Mar 17, 2025, 06:10 ET iOncologi, Inc. Announces the Appointment of Dr. Mona Flores and Mr. Paolo Fundarò to Its Board of Directors
sciences-focused VC firm investing in early-stage drug development. He was formerly the CEO of Genextra, where he played a key role in guiding biotechnology and medical device companies through growth and commercialization. His financial and operational expertise will be instrumental in shaping iOncologi's
More news about: iOncologi, Inc.
Mar 17, 2025, 06:00 ET Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies
March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of
More news about: Chance Pharmaceuticals
Mar 17, 2025, 05:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Lawsuit - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Mar 17, 2025, 05:00 ET Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, today announced it has closed $150
More news about: Latigo Biotherapeutics
Mar 16, 2025, 11:45 ET Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company
insufficient to shield the company from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 15, 2025, 06:07 ET Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today presents on its novel SKY-0515 small molecule
More news about: Skyhawk Therapeutics
Mar 14, 2025, 19:42 ET iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors
biopharmaceutical company focused on advancing immunotherapy platform technologies, today announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi's capabilities in developing
More news about: iOncologi, Inc.
Mar 14, 2025, 16:21 ET ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Mar 14, 2025, 04:23 ET Accropeutics Secured $12 Million in Series B Plus Financing
March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases,
More news about: Accropeutics
Mar 13, 2025, 18:15 ET INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
MEETING, Pa., March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 13, 2025, 16:07 ET Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Mar 13, 2025, 16:05 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Glancy Prongay & Murray LLP
Mar 13, 2025, 16:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Mar 13, 2025, 13:05 ET Multi-Use Bioreactor Market in Pharmaceuticals and Research Institutions to Hit USD 12.26 Billion by 2029, Growing 9.7% Annually | Valuates Reports
infrastructure reinforces the market's long-term growth trajectory, positioning multi-use bioreactors as indispensable assets in pharmaceutical and biotechnology sectors. Unlock Insights: View Full Report Now!
More news about: Valuates Reports
Mar 13, 2025, 10:08 ET PranaX Licenses Exosome Technology to Commercialize Stem Cell Exosomes
www.pranax.com), an emerging regenerative medicine biotechnology company, today announced that it has licensed exosome technology from The University of Texas MD Anderson Cancer Center
More news about: PranaX
Mar 13, 2025, 10:00 ET Coronado Research Announce the Appointment of Nick Littlebury as EVP, Regulatory Affairs
Coronado Research Coronado Research is a consultancy-led, professional services organisation, which provides support to pharmaceutical, biotechnology, and medical device companies. Our objective is to optimise the clinical development process by leveraging all the data available using AI, ML,
More news about: Coronado Research
Mar 13, 2025, 09:37 ET Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference
multimedia:https://www.prnewswire.com/news-releases/immorta-bio-presents-senovax-mediated-tumor-remission-data-at-international-biotechnology-conference-302401123.html
More news about: Immorta Bio Inc.
Mar 13, 2025, 09:03 ET Duly Health Brings Genetic-Based Weight Loss Treatment to Chicago with MyPhenome Test
Phenomix Sciences (Phenomix), a precision medicine biotechnology company that uses data intelligence to treat obesity, today announces its
More news about: Phenomix Sciences
Mar 13, 2025, 09:00 ET Caliber Launches 4 Analytics and AI-driven Solutions to Revolutionize Pharma Manufacturing and Quality
With over 23 years of global expertise, Caliber continues to transform pharmaceutical and biotechnology companies with GxP Quality solutions across Quality Control, Quality Assurance, Manufacturing, and Data and Insights. These solutions help companies
More news about: Caliber Technologies
Mar 13, 2025, 09:00 ET Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation
the life sciences sector through flagship use cases. About Insilico Medicine Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company
More news about: Insilico Medicine
Mar 13, 2025, 09:00 ET UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Mar 13, 2025, 08:00 ET Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
Bracco family of companies. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start–up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics Ltd
Mar 13, 2025, 07:30 ET Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role
More news about: Virax Biolabs
Mar 13, 2025, 07:00 ET Ginsenoside Supplement Redsenol-1 Plus Included in National Cancer Institute's Drug Dictionary
solution for cancer-related fatigue. About Canada Royal Enoch Phytomedicine Ltd.Canada Royal Enoch Phytomedicine Ltd. is a biotechnology company specializing in the research, production, and sales of natural plant-based health products. The company's flagship brand, Redsenol® (also
More news about: Canada Royal Enoch Phytomedicine Ltd.
Mar 13, 2025, 05:45 ET ICON Public Limited Company Class Action: The Gross Law Firm Reminds ICON Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm